About the Conference

The World Conference on Oncology and Cancer Genomics 2026 is designed to accelerate progress in precision oncology through groundbreaking genomic discoveries. The conference’s core objectives are articulated through its vision and mission, which are intrinsically linked to the broader imperative of translating scientific advancements into global clinical impact.

Vision and Mission: Accelerating Precision Oncology Through Genomic Discovery

The conference envisions itself as the leading global platform for advancing the understanding and application of cancer genomics, thereby driving transformative breakthroughs in precision oncology and patient care worldwide. This aspiration is rooted in the recognition that the future of cancer treatment lies in highly individualized strategies informed by detailed genomic insights.

The mission of the conference is to convene leading scientists, clinicians, industry innovators, and policymakers to foster interdisciplinary collaboration, disseminate cutting-edge research, and translate genomic discoveries into actionable clinical strategies for the prevention, diagnosis, and treatment of cancer. This emphasis on translation aligns with the strategic direction observed in major oncology meetings, such as the ASCO 2026 Annual Meeting, which centers on “translating scientific discovery into impact for every patient, in every setting, around the world”. Similarly, the ESMO Targeted Anticancer Therapies (TAT) Congress focuses on “new drug development,” “new targets,” and the integration of “AI in drug development”. The 12th International Clinical Cancer Genomics Conference also explicitly aims to “Accelerate Progress in Precision Medicine for Cancer”. The consistent focus across these prominent events highlights that mere discovery is insufficient; the true measure of scientific progress is its successful application to patient benefit. Therefore, the conference’s foundational principles are built upon bridging the gap between foundational genomic science and its tangible clinical utility.  

Key Themes and Focus Areas: Navigating the Genomic Landscape of Cancer

The conference program will delve into the most critical and rapidly evolving areas within oncology and cancer genomics, fostering a holistic understanding that spans from basic scientific principles to their practical clinical implementation.

  • Precision Medicine & Targeted Therapies: This theme will explore how genomic insights enable individualized treatment strategies and drive the development of novel targeted agents. This area is central to discussions at events like the AACR Special Conference in Cancer Research: “Translating Targeted Therapies in Combination with Radiotherapy” and the “Industry/Academia Precision Oncology Symposium”. The objective is to move beyond conventional, broad-spectrum treatments towards therapies precisely tailored to a patient’s unique genetic profile.  
  • Cancer Genomics & Molecular Diagnosis: Sessions will offer deep dives into the latest advancements in genomic profiling, the identification of cancer biomarkers, and their application in molecular diagnostics for early detection, prognosis, and treatment selection. This constitutes a core focus for specialized events such as the “International Congress of Cancer Genomics”. The EACR annual congress also features a dedicated “Cancer Genomics” section within its abstract collections, underscoring the foundational role of this discipline in cancer research.  
  • Liquid Biopsy: From Discovery to Clinical Implementation: Comprehensive sessions will be dedicated to the utility of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other liquid biopsy components. These non-invasive methods are increasingly vital for monitoring minimal residual disease (MRD), detecting early relapse, and guiding immunotherapy. The prominence of liquid biopsy is evident across numerous conferences, including AACR’s “Liquid Biopsy: From Discovery to Clinical Implementation” and various BLOODPAC events. The extensive research presented at the EACR 2022 Congress, for instance, demonstrated the application of liquid biopsy for monitoring molecular residual disease in head and neck squamous cell carcinoma (EACR22-0855), profiling cell-free DNA methylomes for small cell lung cancer detection (EACR22-1218), and establishing CTC-derived explant models to identify therapeutic opportunities in non-small cell lung cancer (EACR22-0715). The widespread and diverse applications of liquid biopsy underscore its role not merely as a diagnostic tool but as a critical enabler for precision oncology across multiple stages of cancer management, from initial detection to long-term monitoring and resistance tracking.  
  • Immunotherapy & Immuno-genomics: This area will explore the intricate intersection of genomics with immune responses, novel immunotherapeutic strategies, and the identification of biomarkers that predict treatment response or resistance. This topic is consistently featured in major oncology programs, including AACR’s “Tumor Immunology and Immunotherapy” and specialized events like the “Immunogenomics Symposium”.  
  • Computational Biology & Artificial Intelligence in Oncology: The conference will showcase advancements in bioinformatics, machine learning, and artificial intelligence (AI) for drug discovery, clinical trial design, biomarker identification, and personalized treatment prediction. The pervasive influence of AI is highlighted across various scientific gatherings, including ESMO TAT Congresses , ASCO Breakthrough , AACR conferences on “AI, Diagnosis, and Imaging” and “Translating Cancer Evolution and Data Science” , and the Human Genome Meeting. The EACR 2022 abstract book featured an extensive “Bioinformatics and Computational Biology” section, with studies ranging from AI-powered pan-species computational pathology (EACR22-0491) to automated prediction of drug response in hepatocellular carcinoma (EACR22-0088). This widespread integration signifies that AI is no longer a peripheral tool but a fundamental component transforming cancer research, diagnostics, and clinical decision-making across the entire continuum of oncology.  
  • Drug Resistance & Tumor Evolution: This theme will focus on understanding the complex mechanisms of drug resistance and tumor heterogeneity, and on developing strategies to overcome these challenges through advanced genomic and molecular profiling. The EACR abstract book, for instance, includes a dedicated section on “Drug Resistance” , reflecting its critical importance in improving long-term patient outcomes.  
  • Translational Research & Clinical Trials: Bridging the gap between basic scientific discoveries and their practical application in clinical practice will be a central focus, encompassing innovative trial designs and the integration of real-world data. This is a core tenet of ASCO’s 2026 theme, which emphasizes moving science “from bench to bedside” and “to society” , and is a key objective for ESMO TAT, which aims to improve the conduct of early phase clinical trials.  
  • Prevention & Early Detection: Genomic approaches for risk prediction, screening, and the interception of cancer will be explored, highlighting the potential for genomics to revolutionize proactive cancer management. This area is a key focus for AACR’s “Precision Prevention, Early Detection, and Interception of Cancer” conferences.  

Why Attend: Unlocking Opportunities in Cancer Genomics

Attending the World Conference on Oncology and Cancer Genomics 2026 offers unparalleled opportunities for professional growth and scientific advancement.

  • Cutting-Edge Science: Participants will gain access to the latest unpublished research and groundbreaking discoveries presented by global leaders in the field. This provides an invaluable opportunity to be at the forefront of scientific progress.  
  • Networking & Collaboration: The conference provides extensive opportunities to connect with peers, establish new partnerships, and foster interdisciplinary collaborations across academia, industry, and clinical practice. The consistent emphasis on networking and collaboration across various conference descriptions, from EACR to ESMO TAT and the Human Genome Meeting, indicates that these events are designed not just for information dissemination but for community building and fostering future scientific progress. These connections are frequently the catalysts for new research projects, career advancements, and the broader progression of the field.  
  • Professional Development: Attendees can enhance their knowledge, refine their skills, and stay abreast of evolving trends and technologies in cancer genomics and precision oncology. Practical workshops and diverse session formats contribute to a comprehensive learning experience.  
  • Clinical Impact: The program is designed to equip healthcare providers with practical tools and knowledge to translate genomic insights into improved patient care and clinical outcomes. This focus ensures that the scientific discussions have direct relevance to real-world clinical challenges.  
  • Visibility & Recognition: For presenters, the conference offers a unique platform to showcase their work, receive constructive peer feedback, and significantly increase their professional credibility within the global oncology community.  
  • Publication Potential: Accepted abstracts may be considered for publication in a high-impact journal supplement, similar to how EACR abstracts are published in Molecular Oncology or ESMO TAT abstracts appear in   ESMO Open. This opportunity provides a formal, citable record of the research presented, adding significant academic prestige and long-term value for presenters beyond the immediate conference experience.